Overview and Scope
Coronavirus (COVID-19) current therapy refers to a drug created and used to treat mild to moderate COVID-19 in those who have a higher risk of experiencing significant illness as a result of COVID-19.
Sizing and Forecast
The coronavirus (covid-19) current therapy market size has declined steeply in recent years. It will decline from $11.73 billion in 2023 to $5.87 billion in 2024 at a compound annual growth rate (CAGR) of -50.0%. The decline in the historic period can be attributed to limited treatment options, varying treatment efficacy, supply chain disruptions, rapidly evolving scientific knowledge, emergence of variants.
The coronavirus (covid-19) current therapy market size is expected to see steep decline in the next few years. It will decline to $2.34 billion in 2025 at a compound annual growth rate (CAGR) of -60.1%. The decline in the forecast period can be attributed to global vaccine rollout impact, long-term effects and chronic cases, regulatory and market access challenges, global economic factors. Major trends in the forecast period include investing in developing monoclonal antibody therapies, convalescent plasma therapies, cell-based therapies, and antiviral therapies, collaboration with government institutions and undergoing strategic partnerships with other pharmaceutical companies.
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/coronavirus-current-therapy-global-market-report
The coronavirus (covid-19) current therapy market covered in this report is segmented –
1) By Drug Type: Antiviral, Monoclonal Antibodies, Corticosteroid, Supplements, Antimalarial, Interferons And Interleukin Inhibitors, Other Anti-Infective Drugs, Others
1) By Route Of Administration: Oral, Intravenous
2) By End-User: Hospitals, Clinics, Home Care, Others
North America is the largest region in the coronavirus (COVID-19) current therapy market in 2023. Middle East is expected to be the fastest growing region in the global coronavirus (COVID-19) current therapy market share during the forecast period. The regions covered in the coronavirus (covid-19) current therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3247&type=smp
Major Driver Impacting Market Growth
The outbreak of the pandemic COVID-19 contributed to the growth of the coronavirus (COVID-19) current therapy market. The World Health Organization (WHO) declared the outbreak a global pandemic. For instance, in August 2022, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, the global COVID-19 cases reached 581.8 million. As there is no officially approved drug for COVID-19, the demand has risen significantly for repurposed drugs that are used for corona therapy. Countries across the world are facing shortages of drugs, and drug manufacturers are ramping up production to meet the global demand. The Coronavirus Treatment Acceleration Program (CTAP) is a special emergency program initiated by the FDA for the development of potential COVID-19 therapies to be made available to patients as quickly as possible.
Key Industry Players
Major companies operating in the coronavirus (covid-19) current therapy market report are Gilead Sciences, Inc., F. Hoffmann-La Roche AG, Ipca Laboratories Limited, Zydus Cadila, Regeneron Pharmaceuticals, Inc., Sun Pharmaceutical Industries Limited, AbbVie, Glenmark Pharmaceuticals Limited, Eli Lilly and Company, Wallace Pharmaceuticals, Inc., Mylab Discovery Solutions, Kalbe Farma, He Qi Group Foundation, Beijing Jinwofu Bioengineering Technology Company, Zhejiang Orient Gene Biotech Co. Ltd, Transasia Bio Medicals, Vanguard Diagnostics, HLL Lifecare Limited, Voxtur Bio Ltd, Biocryst Pharma, Clover Biopharmaceuticals, Inovio Pharmaceuticals, Inc., LAB-CARE Diagnostics, ImmunoScience, CPC Diagnostics, Sysmex Corporation, Atomo Diagnostics, Cellmid Limited, Moderna Therapeutics, Novavax, Bravovax, Ascletis Pharma, Altimmune, Hunan Lituo Biotechnology, Hangzhou Biotest Biotech, AmonMed Biotechnology, Getein Biotech, Beijing Tigsun Diagnostics, Vivacheck Lab, Seegene, SD Biosensor, Fujirebio, Siemens Healthcare Pte. Ltd., Senova, LetsGetChecked, Omega Diagnostics, Abingdon Health, Babylon, Motologic, F. Hoffmann-La Roche Ltd., Novacyt Group, AstraZeneca, Pfizer, Zentiva, Boehringer Ingelheim, GlaxoSmithKline, Merck & Co., Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi, Amgen and AdaptiveBiotechnologies, BioNtech, Cytodyn, Heat biologics, Johnson&Johnson, Takeda pharmaceuticals, Vaxart, Vir Biotechnology, Victory Square Health, Abbott Molecular Inc., ACRO Biotech, Advagen Biotech Ltd, BD, Boditech Med, Inc., Cellex Inc., CerTest Biotec, S.L., Hi Technologies, BATM, BioMedomics Quant Lease, CapeBio, Astel Diagnostics, Canary Health Technologies, Thermo Fisher Scientific
The covid-19 (covid-19) current therapy market report table of contents includes:
1. Executive Summary
2. Market Characteristics
3. Market Trends And Strategies
4. Impact Of COVID-19
5. Market Size And Growth
6. Segmentation
7. Regional And Country Analysis
.
.
.
27. Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
